Nevada Prescription Monitoring Program Enhancement Project

The Comprehensive Addiction and Recovery Act (CARA) Program is the first major federal substance use disorder treatment and recovery legislation in 40 years and the most comprehensive effort to address the opioid epidemic. CARA establishes a comprehensive, coordinated, and balanced strategy through enhanced grant programs that expand prevention and education efforts while also promoting treatment and recovery. The Comprehensive Opioid Abuse Site-based program was developed as part of the CARA legislation signed into law on July 22, 2016.

The Comprehensive Opioid Abuse Site-based Program aims to reduce opioid abuse and the number of overdose fatalities, as well as to mitigate the impacts on crime victims. The program also supports the implementation, enhancement, and proactive use of prescription drug monitoring programs to support clinical decision making and prevent the abuse and diversion of controlled substances.

The Harold Rogers Prescription Drug Monitoring Program (PDMP) is incorporated into the FY 2018 Comprehensive Opioid Abuse Site-based Program. The purpose of this program is to improve collaboration and strategic decision-making of regulatory and law enforcement agencies and public health officials to address prescription drug and opioid misuse, save lives, and reduce crime. This is made possible through the collection and analysis of controlled substance prescription data and other scheduled chemical products through a centralized database administered by an authorized state agency.

The Nevada State Board of Pharmacy will support the proactive use of the PDMP by providing practitioners with one-click, in-workflow access to patient information by (1) enhancing the Nevada PMP with the addition of NarxCare Enterprise platform, (2) improving the quality and accuracy of PMP data through an extension of the Board of Pharmacy and PMP’s current Audit Project, which looks at the accuracy and completeness of the data in the Nevada PMP, and (3) enhancing the PMP’s ability to provide quality reports of suspected fraudulent or otherwise unlawful or inappropriate prescribing patterns to authorized law enforcement agencies and/or occupational licensing boards for further investigation.

CA/NCF